Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

144.49 +0.15 (+0.10%)
Streaming Delayed Price Updated: 10:45 AM EST, Jan 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
54 55 Next >
News headline image
GSK Challenges Xolair Dominance with $2.2 Billion Acquisition of RAPT Therapeutics
In a bold strategic opening to the 2026 fiscal year, pharmaceutical giant GSK (NYSE:GSK) has announced a definitive agreement to acquire RAPT Therapeutics (Nasdaq:RAPT) for approximately $2.2 billion.... 
Via MarketMinute
Topics Intellectual Property
Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Value Investment Case ↗
Via Chartmill
News headline image
Silicon Meets Science: NVIDIA and Eli Lilly Launch $1 Billion AI Lab to Engineer the Future of Medicine
In a move that signals a paradigm shift for the pharmaceutical industry, NVIDIA (NASDAQ: NVDA) and Eli Lilly and Company (NYSE: LLY) have announced the launch of a $1 billion joint AI co-innovation... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
International Exposure: SPDW's Lower Costs vs. URTH's U.S. Giants ↗
Explore how differences in regional focus, sector exposure, and portfolio makeup may impact your ETF investing strategy. 
Via The Motley Fool
Topics ETFs
News headline image
The Atomic Revolution: How AlphaFold 3 is Redefining the Future of Medicine
In a milestone that many researchers are calling the "biological equivalent of the moon landing," AlphaFold 3 has officially moved structural biology into a new era of predictive precision. Developed... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
NVS Stock Rises After FDA Grants Breakthrough Therapy Designation For Autoimmune Disorder Treatment ↗
Novartis looks to submit data from its many trials of Ianalumab with health authorities starting in early 2026 for potential approval. 
Via Stocktwits
News headline image
The Atomic Revolution: How AlphaFold 3’s Open-Source Pivot Has Redefined Global Drug Discovery in 2026
The decision by Google DeepMind and its commercial sister company, Isomorphic Labs, to fully open-source AlphaFold 3 (AF3) has emerged as a watershed moment for the life sciences. As of January 2026,... 
Via TokenRing AI
Topics Artificial Intelligence Derivatives Economy
News headline image
The Silicon Laureates: How the 2024 Nobel Prizes Cemented AI as the New Language of Science
The announcement of the 2024 Nobel Prizes in Physics and Chemistry sent a shockwave through the global scientific community, signaling a definitive end to the "AI Winter" and the beginning of what... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
IEFA vs. SPDW: Broad International Exposure With Different Portfolio Designs ↗
The iShares Core MSCI EAFE ETF and the SPDR Portfolio Developed World ex‑US ETF may look similar on paper, but each offers a distinct approach to owning international stocks outside the U.S. 
Via The Motley Fool
Topics ETFs
News headline image
The Silicon Laureates: How 2024’s ‘Nobel Prize Moment’ Rewrote the Laws of Scientific Discovery
The history of science is often measured in centuries, yet in October 2024, the timeline of human achievement underwent a tectonic shift that is only now being fully understood in early 2026. By... 
Via TokenRing AI
Topics Artificial Intelligence Electric Vehicles
News headline image
The Digital Microscope: How AlphaFold 3 is Decoding the Molecular Language of Life
As of January 2026, the landscape of biological research has been irrevocably altered by the maturation of AlphaFold 3, the latest generative AI milestone from Alphabet Inc. (NASDAQ: GOOGL). Developed... 
Via TokenRing AI
Topics Artificial Intelligence Bonds
News headline image
SLS Stock In Spotlight On EU Expansion For Cancer Therapy – Retail Says Potential Catalyst For Buyout ↗
The IMPACT-AML program will conduct a European clinical study evaluating SLS009 and provide SELLAS access to multiple clinical sites and a broader patient population. 
Via Stocktwits
News headline image
Viatris Inc. (NASDAQ: VTRS): Navigating the Pivot from Integration to Innovation
Date: January 14, 2026 Viatris Inc. (NASDAQ: VTRS) stands at a critical crossroads in early 2026. After years of functioning as a complex, debt-laden conglomerate formed from the massive merger of... 
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
Travere Therapeutics Shares Fall After FDA Extends Filspari Review for FSGS
On January 13, 2026, Travere Therapeutics (NASDAQ: TVTX) faced a sharp reversal of fortune as the U.S. Food and Drug Administration (FDA) announced a three-month extension for its review of Filspari... 
Via MarketMinute
News headline image
Amgen at the Crossroads: MariTide, Market Volatility, and the Quest for Obesity Dominance
Date: January 13, 2026 Introduction Amgen Inc. (NASDAQ: AMGN) finds itself at a historic crossroads. Long regarded as the "blue-chip" anchor of the biotechnology sector, the Thousand Oaks-based giant... 
Via PredictStreet
Topics Economy Intellectual Property
News headline image
The Evolution of a Giant: A Deep Dive into the ‘New’ Johnson & Johnson (JNJ) in 2026
As of January 13, 2026, Johnson & Johnson (NYSE: JNJ) stands at a pivotal juncture in its nearly 140-year history. Once a sprawling conglomerate synonymous with baby shampoo and Band-Aids, the "New... 
Via PredictStreet
Topics Artificial Intelligence Bankruptcy Economy
News headline image
Why Tempus AI Stock Rose Today ↗
The data provider's artificial intelligence-driven solutions are accelerating drug discovery. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Beyond the Protein: How AlphaFold 3 Redefined the Blueprint of Life and Accelerated the Drug Discovery Revolution
In the two years since its unveiling, AlphaFold 3 (AF3) has fundamentally transformed the landscape of biological research, moving the industry from simple protein folding to a comprehensive "all-atom"... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Is Novartis AG Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
3 Dividend Stocks to Buy in 2026 and Hold Forever ↗
All three offer much more than a regular payout. 
Via The Motley Fool
News headline image
MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation
MoonLake Immunotherapeutics (NASDAQ: MLTX) shares have experienced a dramatic resurgence this week, climbing over 40% following a pivotal regulatory update that has effectively cleared the path for its... 
Via MarketMinute
Topics Intellectual Property
News headline image
BioNTech Finalizes CureVac Acquisition: A Strategic Consolidation Met with Market Skepticism
In a move that signals the end of an era for independent mRNA pioneers, BioNTech SE (Nasdaq: BNTX) has officially completed its acquisition of longtime rival CureVac N.V. (Nasdaq: CVAC). The... 
Via MarketMinute
Topics Intellectual Property
J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs ↗
Via Stocktwits
Topics Government
News headline image
Trade War 2.0: Markets Braced as Trump’s 2026 Tariff ‘Salvos’ Reshape the Global Supply Chain
As of January 8, 2026, the global financial landscape is undergoing a seismic shift driven by President Trump’s latest round of "tariff salvos." These aggressive trade policies, which dominated the... 
Via MarketMinute
Topics Economy Government World Trade
News headline image
New Investors: 3 Stocks to Build Your Portfolio Around in 2026 ↗
These stocks listed here have excellent valuations, promising growth prospects, and they pay dividends. 
Via The Motley Fool
News headline image
The Great Thaw: Biotech Fundraising Surges as Monte Rosa and Genelux Tap Reopening Markets
The biotechnology sector, long frozen in a capital-starved "biology winter," is showing definitive signs of a seasonal shift. On January 7, 2026, the industry witnessed a significant injection of... 
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
Why Salesforce Rose 16% in December ↗
The cloud stock gained after a better-than-expected earnings report. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Why Did GLUE Stock Surge Over 50% In Premarket Today? ↗
Monte Rosa Therapeutics reported positive interim Phase 1 data for MRT-8102, showing significant anti-inflammatory effects in patients with elevated cardiovascular risk. 
Via Stocktwits
News headline image
U.S. Scales Back The Number Of Vaccines It Recommends For Every Child ↗
Move comes in response to a presidential memorandum issued by President Donald Trump in December, aimed at aligning U.S. vaccination practices with other developed nations. 
Via Stocktwits
Topics Government
News headline image
The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500
As the calendar turns to 2026, Alnylam Pharmaceuticals (Nasdaq: ALNY) stands at the threshold of a new era. Once a speculative pioneer in the arcane world of RNA interference (RNAi), the... 
Via PredictStreet
Topics Economy Intellectual Property Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
54 55 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.